New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:26 EDTINCY, PCYCNomura is a buyer of Incyte and Pharmacyclics into ASCO meetings
Nomura is a buyer of Incyte (INCY) and Pharmacyclics (PCYC) following the ASCO abstract releases. The firm expects 50mg dose data on June 2 to meet investor expectations and for shares to recover. For Pharmacyclics, the analyst expects investor focus to be on negativity rates of Phase I/II trial of competitor ABT-199 + Rituxan and Imbruvica RESONATE Phase III data on June 3.
News For INCY;PCYC From The Last 14 Days
Check below for free stories on INCY;PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
August 18, 2014
16:08 EDTPCYCPharmacyclics names Shawn Cline Tomasello as Chief Commercial Officer
Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4B in revenue. Prior to joining Celgene, Cline Tomasello was the National Director of Hematology for Rituxan at Genentech, where she was responsible for over $1.7B in revenue.
August 8, 2014
08:17 EDTPCYCPharmacyclics announces Jesse McGreivy to step down from Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use